FDA to test out nutrition labels on the front of food packaging
The United States Food and Drug Administration will test out labels on the front of food packages in the hope of giving shoppers better access to nutrition information, the agency said. The goal is to address diet-related chronic disease by “empowering consumers with nutrition information to help them more easily identify healthier choices and encouraging industry innovation to produce healthier foods,” the FDA said in a recent regulatory filing.
Noting that a food is “fat free,” for example, may lead some people to think a particular food is a healthy choice, when in fact fat is an important macronutrient, she said. A person might see that one food is labeled as having lower calories than another, but not take into consideration the protein and fiber, which may be a better indicator of what would be a healthier choice for that person, she added.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
FDA OKs Drug for Cholestatic Pruritus in Alagille SyndromeOdevixibat is indicated for treatment of cholestatic pruritus associated with Alagille syndrome in patients as young as 12 months. It marks the second indication for the drug.
Read more »
FDA OKs Low-Dose Colchicine for Broad CV IndicationThe drug represents the first specific anti-inflammatory drug for the reduction of cardiovascular events for patients with established atherosclerotic disease or with multiple risk factors.
Read more »
FDA Warns of Tattoo Ink Tied to Dangerous InfectionsThe FDA released the new draft guidance aiming to reduce the use of pathogen-contaminated tattoo ink, which can cause stubborn infections that are especially hard to treat, dermatologists said.
Read more »
FDA OKs Empagliflozin for Children With Type 2 DiabetesThe FDA has approved empagliflozin and empagliflozin combined with metformin for the treatment of type 2 diabetes in children aged 10 years and older.
Read more »
FDA Approves Talazoparib for Metastatic Prostate CancerThe oral PARP inhibitor talazoparib in combination with enzalutamide provides a new treatment option for patients with HRR gene–mutated metastatic castration-resistant prostate cancer.
Read more »
US FDA approves Eli Lilly-Boehringer's diabetes drugs for childrenThe U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and Synjardy to treat type 2 diabetes in children.
Read more »